title: Stevens-Johnson syndrome after treatment with bendamustine.
authors.forename: Matteo
authors.initials: M
authors.lastname: Lambertini
authors.forename: Lucia
authors.initials: L
authors.lastname: Del Mastro
authors.forename: Giovanni
authors.initials: G
authors.lastname: Gardin
authors.forename: Alessia
authors.initials: A
authors.lastname: Levaggi
authors.forename: Claudia
authors.initials: C
authors.lastname: Bighin
authors.forename: Sara
authors.initials: S
authors.lastname: Giraudi
authors.forename: Paolo
authors.initials: P
authors.lastname: Pronzato
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D005260:Female; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride